Lipanthyl Supra

Fenofibrate, the active ingredient in Lipanthyl Supra, is a fibrate presented as a micronised oral tablet for oral use. It lowers elevated triglycerides and cholesterol in patients with dyslipidaemia, helping to manage hypertriglyceridaemia, mixed dyslipidaemia and primary hypercholesterolaemia as part of a comprehensive lipid‑lowering regimen.

GNH USA supplies Lipanthyl Supra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers, including regulatory documentation and temperature‑controlled logistics where required.

Lipanthyl Supra (fenofibrate) is used to treat lipid disorders by reducing triglyceride‑rich lipoproteins.

Hypertriglyceridemia: reduces very‑low‑density lipoprotein (VLDL) and triglyceride levels. Mixed dyslipidemia: lowers triglycerides while modestly increasing HDL‑cholesterol. Primary hypercholesterolemia (adjunct): improves overall lipid profile when combined with statin therapy.

Fenofibrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increase in ALT/AST. - Muscle pain: mild myalgia without weakness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Severe liver injury: marked hepatitis or hepatic failure. - Hypersensitivity reactions: rash, pruritus or angioedema.

Before prescribing Lipanthyl Supra, clinicians should consider several precautionary measures to ensure safe use.

Renal function: assess creatinine clearance in patients with renal impairment. Liver disease: avoid or monitor in active hepatic disease. Gallbladder disease: use with caution in patients with gallstones. Drug interactions: review concomitant medications that affect CYP enzymes. Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Fenofibrate can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of myopathy and rhabdomyolysis. - Cyclosporine: may raise fenofibrate plasma levels, enhancing toxicity. - Warfarin: can potentiate anticoagulant effect, increasing INR.

Moderate Interactions (Monitor Closely): - Statins (especially high‑dose simvastatin): increased risk of muscle toxicity. - Antidiabetic agents: fenofibrate may affect glycemic control. - Thiazide diuretics: may increase serum uric acid, precipitating gout.